Xap Therapeutics

Xap Therapeutics is a Cambridge-based biotechnology company developing a synthetic biology platform for next-generation cell therapeutics.

The company applies CRISPR technology to engineer induced pluripotent stem cells (iPSCs) into a universal "chassis" cell that can be functionalised with engineered receptors and cargo-release mechanisms, enabling programmable responses to disease cues.

Its pipeline targets oncology and autoimmune diseases with mechanisms beyond the reach of conventional cell therapy approaches.